Gara Jalqabaatti › Myeloma Baay’ee › Michigan › Detroit
Qorannoo klinikaalii Myeloma Baay’ee Detroit, MI keessatti
Qorannoo 19 Myeloma Baay’ee f Detroit fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Karmanos Cancer Institute, Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Namoota walitti qabaa jiraSadarkaa 3
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Namoota walitti qabaa jiraSadarkaa 4
- Barbara Ann Karmanos Cancer Institute, Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Henry Ford Health Saint John Hospital, Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Henry Ford Health System, Detroit
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Namoota walitti qabaa jiraSadarkaa 3
- Henry Ford Health Saint John Hospital, Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Namoota walitti qabaa jiraSadarkaa 1/2
- Karmanos Cancer Institute, Detroit
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Detroit
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Karmanos Cancer Institute, Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Namoota walitti qabaa jiraSadarkaa 1
- Karmanos Cancer Institute, Detroit
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Namoota walitti qabaa jiraSadarkaa 4
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Namoota walitti qabaa jiraSadarkaa 3
- Ascension Saint John Hospital, Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Karmanos Cancer Institute, Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Namoota walitti qabaa jiraSadarkaa 1/2
- Karmanos Cancer Institute, Detroit
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Namoota walitti qabaa jiraSadarkaa 3
- GSK Investigational Site, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Namoota walitti qabaa jira
- Karmanos Cancer Institute, Detroit
Qorannoo Myeloma Baay’ee magaalota biroo keessatti
- New York City, NYQorannoo 60
- Boston, MAQorannoo 42
- Atlanta, GAQorannoo 41
- Houston, TXQorannoo 38
- Durham, NCQorannoo 37
- Nashville, TNQorannoo 32
- Denver, COQorannoo 27
- Rochester, MNQorannoo 24
- St. Louis, MOQorannoo 24
- Columbus, OHQorannoo 24
- Baldwin Park, CAQorannoo 23
- Chicago, ILQorannoo 22
Qorannoo biroo Detroit keessatti
- Kansara Qara'a Non-Small CellQorannoo 44
- Saree OljooQorannoo 33
- Saree (Gosoota Hunda)Qorannoo 29
- Kansarii ColorectalQorannoo 26
- Kansarii OvariiQorannoo 26
- Kansara MetastatikiiQorannoo 24
- Kansarii ProstateQorannoo 22
- Kansa EndometiriyaaliiQorannoo 21
- Dhibee QaraQorannoo 20
- Kanisa HarkaaQorannoo 16
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 15
- Leukemia Myeloidii HamaaQorannoo 14
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.